Maybe a dumb question since I am not a science guy BUT I'll ask anyway . Why don't companies use PEGylation more when developing a protein with potential or even theoretical immunogenicity? Isn't PEG technology fairly advanced that the benefits outway the risks/delays needed to go back and apply it?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.